Ensign Peak Advisors, Inc Gritstone Bio, Inc. Transaction History

Ensign Peak Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.96 - $2.9 $1.31 Million - $1.94 Million	670,000 Added 83.97%	1,467,880 $3.77 Million
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $1.12 Million - $2.05 Million	677,353 Added 561.99%	797,880 $1.56 Million
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $35,400 - $86,800	-20,000 Reduced 14.23%	120,527 $292,000
Q4 2021 Feb 11, 2022	BUY	$8.76 - $13.71 $350,636 - $548,770	40,027 Added 39.83%	140,527 $1.81 Million
Q3 2021 Nov 12, 2021	SELL	$6.41 - $13.54 $1.5 Million - $3.17 Million	-234,136 Reduced 69.97%	100,500 $1.09 Million
Q1 2021 May 12, 2021	SELL	$4.07 - $27.11 $13,247 - $88,243	-3,255 Reduced 0.96%	334,636 $3.16 Million
Q4 2020 Feb 12, 2021	BUY	$2.57 - $4.22 $72,057 - $118,320	28,038 Added 9.05%	337,891 $1.33 Million
Q3 2020 Nov 12, 2020	SELL	$2.63 - $8.09 $954,858 - $2.94 Million	-363,064 Reduced 53.95%	309,853 $822,000
Q2 2020 Aug 12, 2020	BUY	$5.69 - $8.17 $1.84 Million - $2.64 Million	323,401 Added 92.53%	672,917 $4.47 Million
Q1 2020 May 11, 2020	SELL	$5.47 - $11.3 $135,984 - $280,918	-24,860 Reduced 6.64%	349,516 $2.04 Million
Q4 2019 Feb 14, 2020	BUY	$7.07 - $11.61 $2.65 Million - $4.35 Million	374,376 New	374,376 $3.36 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.